The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Second-line (2L) pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Three-year follow up (FU) of the phase 1 KEYNOTE-151 study.
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere
 
Xiaoshi Zhang
No Relationships to Disclose
 
Yongqian Shu
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Di Wu
No Relationships to Disclose
 
Jiwei Liu
No Relationships to Disclose
 
Lili Mao
No Relationships to Disclose
 
Xuan Wang
No Relationships to Disclose
 
Xizhi Wen
No Relationships to Disclose
 
Yanhong Gu
No Relationships to Disclose
 
Lingjun Zhu
No Relationships to Disclose
 
Shijie Lan
No Relationships to Disclose
 
Xin Cai
No Relationships to Disclose
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Haiyan Dai
Honoraria - Merck Sharp & Dohme
 
Cuizhen Niu
Employment - Merck Sharp & Dohme
Honoraria - Merck Sharp & Dohme
 
Lu Si
No Relationships to Disclose